BMS-986001, an HIV nucleoside reverse transcriptase inhibitor, does not degrade mitochondrial DNA in long-term primary cultures of cells isolated from human kidney, muscle, and adipose tissue

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 12, 2013, Pages 6205-6212

  Wang, Faye ^a   Flint, Oliver P ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ADEFOVIR; CELL PROTEIN; FESTINAVIR; MITOCHONDRIAL DNA; STAVUDINE; TENOFOVIR; ZIDOVUDINE; ADENINE; BMS-986001; PHOSPHONIC ACID DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; THYMIDINE;

ADIPOCYTE; ADIPOSE TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL ISOLATION; CELL LINE; CELL VIABILITY; CONTROLLED STUDY; DNA DEGRADATION; DRUG TISSUE LEVEL; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY; KIDNEY CELL; KIDNEY EPITHELIUM; KIDNEY PROXIMAL TUBULE; MAXIMUM PLASMA CONCENTRATION; MITOCHONDRIAL TOXICITY; MUSCLE; MYOTUBE; PRIMARY CELL CULTURE; PRIORITY JOURNAL; SKELETAL MUSCLE; ANALOGS AND DERIVATIVES; CYTOLOGY; DNA FRAGMENTATION; DRUG EFFECTS; EPITHELIUM CELL; MITOCHONDRION; STRUCTURE ACTIVITY RELATION; TOXICITY; ULTRASTRUCTURE;

ADENINE; ADIPOCYTES; DNA FRAGMENTATION; DNA, MITOCHONDRIAL; EPITHELIAL CELLS; HUMANS; KIDNEY TUBULES, PROXIMAL; MITOCHONDRIA; MUSCLE FIBERS, SKELETAL; ORGANOPHOSPHONATES; PRIMARY CELL CULTURE; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; STRUCTURE-ACTIVITY RELATIONSHIP; THYMIDINE;

EID: 84887473284     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01206-13     Document Type: Article

References (40)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. 2012. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, 2012 update. Office of AIDS Research Advisory Council, National Institutes of Health, Department of Health and Human Services, Bethesda, MD. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed May 2012.
2. Clumeck N, Pozniak A, Raffi F. 2008. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIVinfected adults. HIV Med. 9:65-71.
3. World Health Organization. 2010. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach, 2010 revision. World Health Organization. http://www.who.int/hiv/pub/arv/adult2010/ en/index.html. Accessed August 2012.
4. Bedimo R, Maalouf NM, Zhang S, Drechsler H, Tebas P. 2012. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS 26:825-831.
5. Scherzer R, Estrella M, Li Y, Choi AI, Deeks SG, Grunfeld C, Shlipak MG. 2012. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS 26:867-875.
6. Reynes J, Trinh R, Pulido F, Soto-Malave R, Gathe J, Qaqish R, Tian M, Fredrick L, Podsadecki T, Norton M, Nilius A. 2013. Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviralnaive subjects: 96-week results of the PROGRESS Study. AIDS Res. Hum. Retroviruses 29:256-265.
7. Brinkman K, Smeitink JA, Romijn JA, Reiss P. 1999. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-Therapy-related lipodystrophy. Lancet 354:1112-1115.
8. Hammond E, McKinnon E, Nolan D. 2010. Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences. Clin. Infect. Dis. 51:591-599.
9. Herlitz LC, Mohan S, Stokes MB, Radhakrishnan J, D'Agati VD, Markowitz GS. 2010. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int. 78:1171-1177.
10. Kohler JJ, Hosseini SH, Hoying-Brandt A, Green E, Johnson DM, Russ R, Tran D, Raper CM, Santoianni R, Lewis W. 2009. Tenofovir renal toxicity targets mitochondria of renal proximal tubules. Lab. Invest. 89: 513-519.
11. Lebrecht D, Venhoff AC, Kirschner J, Wiech T, Venhoff N, Walker UA. 2009. Mitochondrial tubulopathy in tenofovir disoproxil fumaratetreated rats. J. Acquir. Immune Defic. Syndr. 51:258-263.
12. Dutschman GE, Grill SP, Gullen EA, Haraguchi K, Takeda S, Tanaka H, Baba M, Cheng YC. 2004. Novel 4=-substituted stavudine analog with improved anti-human immunodeficiency virus activity and decreased cytotoxicity. Antimicrob. Agents Chemother. 48:1640-1646.
13. Tanji N, Tanji K, Kambham N, Markowitz GS, Bell A, D'Agati VD. 2001. Adefovir nephrotoxicity: possible role of mitochondrialDNAdepletion. Hum. Pathol. 32:734-740.
14. Vigano M, Lampertico P, Colombo M. 2011. Drug safety evaluation of adefovir in HBV infection. Expert Opin. Drug Saf. 10:809-818.
15. Flint O, Wang F. 2012. XIX International AIDS Conference, Washington, DC, 22 to 27 July 2012, poster TUPE042.
16. Flint O, Wang F. 2012. 11th International Congress on Drug Therapy in HIV Infection, Glasgow, United Kingdom, 11 to 15 November 2012, poster 051.
17. Cotte L, Dellamonica P, Raffi F, Yazdanpanah Y, Molina JM, Boué F, Urata Y, Chan HP, Zhu L, Chang IH, Bertz R, Hanna GJ, Grasela DM, Hwang C. 2013. Randomized, placebo-controlled study of the safety, tolerability, antiviral activity and pharmacokinetics of 10-day monotherapy with BMS-986001, a novel HIV NRTI, in treatment-experienced HIV-1-infected subjects. J. Acquir. Immune Defic. Syndr. 63:346-354.
18. Birkus G, Hitchcock MJ, Cihlar T. 2002. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 46:716-723.
19. Bazzoli C, Jullien V, Le Tiec C, Rey E, Mentre F, Taburet AM. 2010. Intracellular pharmacokinetics of antiretroviral drugs in HIV-infected patients, and their correlation with drug action. Clin. Pharmacokinet. 49:17-45.
20. Mirzaee S, Eriksson S, Albertioni F. 2010. Differences in cytosolic and mitochondrial 5=-nucleotidase and deoxynucleoside kinase activities in Sprague-Dawley rat and CD-1 mouse tissues: implication for the toxicity of nucleoside analogs in animal models. Toxicology 267:159-164.
21. Rylova SN, Albertioni F, Flygh G, Eriksson S. 2005. Activity profiles of deoxynucleoside kinases and 5=-nucleotidases in cultured adipocytes and myoblastic cells: insights into mitochondrial toxicity of nucleoside analogs. Biochem. Pharmacol. 69:951-960.
22. Mulato AS, Ho ES, Cihlar T. 2000. Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J. Pharmacol. Exp. Ther. 295:10-15.
23. Ho ES, Lin DC, Mendel DB, Cihlar T. 2000. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J. Am. Soc. Nephrol. 11:383-393.
24. Kohler JJ, Hosseini SH, Green E, Abuin A, Ludaway T, Russ R, Santoianni R, Lewis W. 2011. Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters. Lab. Invest. 91:852-858.
25. Cihlar T, Birkus G, Greenwalt DE, Hitchcock MJ. 2002. Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors. Antiviral Res. 54:37-45.
26. Vidal F, Domingo JC, Guallar J, Saumoy M, Cordobilla B, Sanchez de la Rosa R, Giralt M, Alvarez ML, Lopez-Dupla M, Torres F, Villarroya F, Cihlar T, Domingo P. 2006. In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells. Antimicrob. Agents Chemother. 50:3824-3832.
27. Hudson G, Chinnery PF. 2006. Mitochondrial DNA polymerase-gamma and human disease. Hum. Mol. Genet. 15(Spec No 2):R244-R252.
28. Kramata P, Votruba I, Otova B, Holy A. 1996. Different inhibitory potencies of acyclic phosphonomethoxyalkyl nucleotide analogs toward DNA polymerases alpha, delta and epsilon. Mol. Pharmacol. 49:1005-1011.
29. Yang G, Dutschman GE, Wang CJ, Tanaka H, Baba M, Anderson KS, Cheng YC. 2007. Highly selective action of triphosphate metabolite of 4=-ethynyl D4T: a novel anti-HIV compound against HIV-1 RT. Antiviral Res. 73:185-191.
30. Cherrington JM, Allen SJ, Bischofberger N, Chen MS. 1995. Kinetic interaction of the diphosphates of 9-(2-phosphonylmethoxyethyl)adenine and other anti-HIV active purine congeners with HIV reverse transcriptase and human DNA polymerases a, b and g. Antivir. Chem. Chemother. 6:217-221.
31. Papp E, Gadawski I, Cote HC. 2008. Longitudinal effects of thymidine analogues on mtDNA, mtRNA and multidrug resistance (MDR-1) induction in cultured cells. J. Antimicrob. Chemother. 61:1048-1052.
32. Kunz A, Wurmb-Schwark N, Sewangi J, Ziske J, Lau I, Mbezi P, Theuring S, Hauser A, Dugange F, Katerna A, Harms G. 2012. Zidovudine exposure in HIV-1 infected Tanzanian women increases mitochondrial DNA levels in placenta and umbilical cords. PLoS One 7:e41637. doi:10.1371/journal.pone.0041637.
33. Maagaard A, Kvale D. 2009. Long term adverse effects related to nucleoside reverse transcriptase inhibitors: clinical impact of mitochondrial toxicity. Scand. J. Infect. Dis. 41:808-817.
34. Martin JL, Brown CE, Matthews-Davis N, Reardon JE. 1994. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob. Agents Chemother. 38:2743-2749.
35. Anderson PL, Kakuda TN, Lichtenstein KA. 2004. The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities. Clin. Infect. Dis. 38:743-753.
36. Johnson AA, Ray AS, Hanes J, Suo Z, Colacino JM, Anderson KS, Johnson KA. 2001. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J. Biol. Chem. 276:40847-40857.
37. Lee H, Hanes J, Johnson KA. 2003. Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry 42:14711-14719.
38. Lund KC, Wallace KB. 2004. Direct effects of nucleoside reverse transcriptase inhibitors on rat cardiac mitochondrial bioenergetics. Mitochondrion 4:193-202.
39. Lynx MD, Bentley AT, McKee EE. 2006. 3=-Azido-3=-deoxythymidine (AZT) inhibits thymidine phosphorylation in isolated rat liver mitochondria: a possible mechanism of AZT hepatotoxicity. Biochem. Pharmacol. 71:1342-1348.
40. Marroquin LD, Hynes J, Dykens JA, Jamieson JD, Will Y. 2007. Circumventing the Crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants. Toxicol. Sci. 97:539-547.